Affordable Access

deepdyve-link
Publisher Website

Possible immune regulation mechanisms for the progression of chronic thromboembolic pulmonary hypertension.

Authors
  • Miao, Ran1
  • Dong, Xingbei2
  • Gong, Juanni3
  • Wang, Ying4
  • Guo, Xiaojuan5
  • Li, Yidan6
  • Li, Jifeng3
  • Yang, Suqiao3
  • Kuang, Tuguang3
  • Wan, Jun7
  • Liu, Min8
  • Zhai, Zhenguo7
  • Zhong, Jiuchang9
  • Yang, Yuanhua10
  • 1 Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Institute of Respiratory Medicine, Beijing 100020, China. , (China)
  • 2 Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. , (China)
  • 3 Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Institute of Respiratory Medicine, Beijing 100020, China; Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. , (China)
  • 4 Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. , (China)
  • 5 Department of Radiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. , (China)
  • 6 Department of Echocardiography, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. , (China)
  • 7 Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Institute of Respiratory Medicine, Beijing 100020, China; Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, China. , (China)
  • 8 Department of Radiology, China-Japan Friendship Hospital, Beijing 100029, China. , (China)
  • 9 Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. Electronic address: [email protected] , (China)
  • 10 Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Institute of Respiratory Medicine, Beijing 100020, China; Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Thrombosis research
Publication Date
Dec 02, 2020
Volume
198
Pages
122–131
Identifiers
DOI: 10.1016/j.thromres.2020.11.032
PMID: 33316641
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

This study aimed to screen key genes significantly associated with chronic thromboembolic pulmonary hypertension (CTEPH) and predicted suitable drugs for the treatment of CTEPH from the perspective of immune cells. The dataset GSE130391 was used for this analysis. Differentially expressed genes (DEGs) between the CTEPH and control groups were screened. Abundance of infiltrating immune cells was analyzed and immune-related DEGs were identified. Next, the circular RNA (circRNA)-micro RNA (miRNA)-mRNA network was constructed, followed by functional enrichment analysis. Then, the protein-protein interaction (PPI) network was constructed and drug-gene interactions were predicted. Finally, miRNA and circRNA prediction results were verified by our previously published studies. Five key immune cell-related DEGs [CD83 molecule (CD83), complement c5a receptor 1 (C5AR1), atypical chemokine receptor 1 (ACKR1), profilin 2 (PFN2), and solute carrier family 2 member 3 (SLC2A3)] were identified. Several circRNA-miRNA-mRNA interactions were obtained, including circ_0022342miR-503-5pSLC2A3 and circ_0002062miR-92b-3p/miR-92a-3pmannosidase alpha class 2A member 1 (MAN2A1). Immune cell for SLC2A3 was eosinophils and for MAN2A1 was regulatory T cells (Tregs). Additionally, Glufosfamide and Kifunensine might be suitable as candidate drugs for CTEPH treatment. SLC2A3 and MAN2A1 may be important genes for the pathogenesis of CTEPH. Possible immune regulation mechanisms in CTEPH may be circ_0022342miR-503-5pSLC2A3 and circ_0002062miR-92b-3p/miR-92a-3pMAN2A1. These results may be helpful for the diagnosis and treatment of CTEPH from the perspective of immunology. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times